Helix BioPharma Corp. (TSE:HBP – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as C$0.75 and last traded at C$0.75, with a volume of 22,051 shares. The stock had previously closed at C$0.90.
Helix BioPharma Stock Performance
The company has a market cap of C$57.28 million, a PE ratio of -18.75 and a beta of 1.39. The company has a debt-to-equity ratio of 29.27, a quick ratio of 1.03 and a current ratio of 0.19. The firm’s 50 day moving average is C$1.17 and its 200-day moving average is C$1.60.
Helix BioPharma (TSE:HBP – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported C($0.01) EPS for the quarter. On average, research analysts anticipate that Helix BioPharma Corp. will post -0.11 earnings per share for the current fiscal year.
About Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA¿, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA¿, a pre-IND gemcitabine prodrug for advanced solid tumors.
See Also
- Five stocks we like better than Helix BioPharma
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
- D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?
- 5 AI Heavyweights That Look Too Cheap to Ignore After the Sell-Off
- Bonds Are Paying 5% Again, and the Repricing Has Reached Every Corner of the Market
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
